RETATRUTIDE
Last updated: January 6, 2025
For informational purposes only. Not medical advice. Always consult a healthcare professional.
Tried RETATRUTIDE? Be part of the collective knowledge. Share your experience - your insights help others on their journey.
What Is RETATRUTIDE?
Retatrutide is a novel triple agonist targeting GLP-1, GIP, and glucagon receptors. In clinical trials, it produced unprecedented weight loss results, making it potentially the most effective obesity treatment developed.
This is a peptide. Most peptides are research chemicals requiring reconstitution and subcutaneous injection. Purity and storage conditions matter.
Quick Verdict
Up to 24% body weight loss in Phase 2. That number exceeded every other pharmaceutical weight loss agent tested to date. Retatrutide hits three receptors simultaneously (GLP-1, GIP, and glucagon), which is one more than tirzepatide and two more than semaglutide. It is not yet FDA-approved and remains investigational. Phase 3 will determine whether the Phase 2 promise holds. Sentiment is 70/100 across 5 tracked studies.
Evidence Quality
- Human trials: Moderate (Phase 2 completed with striking efficacy data; Phase 3 ongoing)
- Animal evidence: Moderate
- Community reports: Sparse (limited availability as a research compound; some early reports from clinical trial participants)
- Key uncertainty: Whether the glucagon receptor agonism, which drives some of the additional weight loss, has metabolic consequences (particularly hepatic) that will surface in longer Phase 3 trials.
What the Research Shows
Research found retatrutide significantly reduces weight, waist circumference, and BMI. A phase 2 trial demonstrated significant improvements in type 2 diabetes patients. Research also showed potential to significantly lower both systolic and diastolic blood pressure. The 24% body weight loss in Phase 2 is a ceiling, not an average, and outcomes will vary once real-world populations are included. The muscle loss concerns from semaglutide apply here as well, potentially amplified by the additional receptor activity. Early sourcing from research chemical suppliers carries purity and dosing risks.
Who Should Be Cautious
Same contraindications as semaglutide: family history of medullary thyroid carcinoma, personal history of pancreatitis, and MEN2 syndrome. The glucagon component adds theoretical hepatic risk that has not been fully characterized. GI side effects (nausea, vomiting, diarrhea) are common and dose-related.
What This Page Cannot Tell You
Phase 3 results, long-term safety data, and FDA approval status will determine whether retatrutide delivers on the Phase 2 promise. Citing Phase 2 results as proof of efficacy is premature.
What Experts Say
All the celebs now getting that retrutatide look. If you want to know what will be massive on legal RX market 2 years ahead in the fat loss, muscle, vitality space… it always goes from bodybuilding (GH, TRT, GLPs, Retra.) to Hollywood to mainstream. EVERY TIME. Since the 80s.
29%—That's a lot of weight loss, folks. Triple GLP-1 drug receptor retatrutide. Compares with avg weight loss with Zepbound 21%, Wegovy (Ozempic) 15%.
Have a few patients from the retatrutide trials. What they describe is ridiculous in terms of how effective this stuff is. The future of obesity/weight medicine is great!
Quotes sourced from public posts on X or contributed exclusively to Dopamine Club. Views expressed are those of the original authors.
RETATRUTIDE Research & Studies
01 Retatrutide, A Trigonal Glp-1, Gip And Glucagon Receptor Agonist, And Its Role In Weight Reduction ▸
Study found retatrutide significantly reduces weight, waist circumference, and BMI in overweight adults while improving cardiometabolic parameters.
View Study (ScienceDirect)02 Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomized, double-blind, placebo and active-controlled, parallel-group, phase 2 trial ▸
Retatrutide significantly improved blood sugar control and reduced body weight across various doses, demonstrating higher effectiveness than placebo and dulaglutide.
View Study (ScienceDirect)03 The Effect Of Triple-Hormone-Receptor Agonist Retatrutide, A Novel Medication For Weight Loss, On Blood Pressure ▸
Retatrutide showed potential to significantly lower both systolic and diastolic blood pressure based on phase 2 trials.
View Study (ScienceDirect)04 Retatrutide showing promise in obesity (and type 2 diabetes) ▸
Retatrutide led to significant weight loss over 24 weeks but frequently caused gastrointestinal side effects.
View Study (PubMed)05 A review of an investigational drug Retatrutide, a novel triple agonist agent for the treatment of obesity ▸
Retatrutide, in Phase III trials, has shown promising weight loss results in earlier trials, indicating potential for treating obesity.
View Study (PubMed)RETATRUTIDE User Reviews & Experiences
Sentiment score computed from aggregated public user reports, forums, and community discussions. Not a clinical measure.
Early adopters report dramatic weight loss exceeding semaglutide results. Side effects similar to other GLP-1 agonists. Not yet FDA approved but generating significant interest.
RETATRUTIDE Benefits, Dosage & Side Effects
- Dramatic Weight Loss: Up to 24% body weight reduction in trials.
- Triple Action: Targets GLP-1, GIP, and glucagon receptors.
- Metabolic Improvement: Better glucose control and metabolic health.
- Appetite Suppression: Significant reduction in hunger.
- Potential Superiority: May exceed semaglutide and tirzepatide.
- Most Effective Weight Loss: Highest recorded in clinical trials.
- Dose-Dependent: Higher doses produce greater weight loss.
- Under Development: Still in clinical trials.
- Clinical Trial Doses: 1-12mg weekly in phase 2 trials.
- Weekly Injection: Administered once weekly.
- Dose Titration: Started low and increased gradually.
- GI Effects: Nausea, vomiting, diarrhea common.
- Similar to GLP-1s: Side effect profile comparable to semaglutide.
- Dose-Related: Higher doses mean more side effects.
- Generally Manageable: Most side effects decrease over time.
- Not Yet Approved: Still in phase 3 clinical trials.
- Research Chemical: Available from some peptide suppliers.
- Future Availability: Expected FDA review pending trial completion.
Related Compounds
Featured in Protocols
Community Reviews
Share your experience with RETATRUTIDE and help others make informed decisions.
Write a Review
Sign in to leave a review